Phase 2 N=83 Eribulin in HER2 Negative Metastatic BrCa
Breast Cancer
Primary: Overall Response Rate (ORR) — 35.6; 13.2 percentage of participants — p=0.42
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Breast Cancer
Primary: Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen. — 14.3 months
Phase 2 N=140 HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Phase 3 N=564 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
Metastatic Breast Cancer
Primary: Overall Survival (PP Population) — 30.2; 26.1 months — p=0.1983
Phase 2 N=18 Herceptin and GM-CSF for Metastatic Breast Cancer
Breast Cancer
Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants
Phase 2 N=58 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) by Investigator Assessment — 12.3 percentage of participants
Phase 3 N=569 Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
HER2/Neu Over-expressing Locally Advanced Breast Cancer · Metastatic Breast Cancer
Primary: Progressive-free Survival (PFS) Per Investigator Assessment — 7.00; 5.78 months — p=0.0067
Phase 2 N=56 Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Breast Neoplasms
Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants
Phase 2 N=78 Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) of MTD/Phase II Patients — 4.0 months
Phase 3 N=652 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Phase 3 N=736 A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 8.0; 8.7; 8.8 Months — p=0.0318
Phase 2 N=44 A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0…
Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Phase 2 N=61 Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
HER2-positive Breast Cancer · Male Breast Cancer · Recurrent Breast Cancer
Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants
Phase 2 N=55 T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
HER2-positive Breast Cancer · Breast Cancer · Breast Cancer Stage
Primary: Estimate Progression-free Survival — 16.9; 8.3 Months
Phase 2 N=58 Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) Until First Progression — 2.0; 5.7 months
Phase 2 N=140 MEtronomic TrEatment Option in Advanced bReast cAncer
Breast Cancer
Primary: Time to Treatment Failure (TTF) Compared Between Treatment Groups. — 5.7; 8.3 months
Phase 2 N=84 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Grades of Cardiotoxicity Events in the Subset of Patients Reporting a Cardiotoxicity Event — 2; 12; 4; 8 participants
Phase 2 N=225 A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer
Breast Cancer
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors…
Phase 2 N=32 A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
HER-2 Positive Breast Cancer
Primary: Intracranial Objective Response Rate- Modified RECIST Criteria — 0; 1; 17; 8 Participants
Phase 2 N=111 Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 9.1; 7.1 months
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 2 N=104 MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Breast Cancer Metastatic
Primary: Clinical Benefit Rate at 24 Weeks — 3; 18; 9 Participants
Phase 2 N=33 A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Part I: Progression Free Survival (PFS) by Biomarker — NA; NA; 13.963; 1.216 months
Phase 3 N=608 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Breast Cancer
Primary: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer…
Phase 4 N=44 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
First or Second Line HER2-negative Breast Cancer · Metastatic Disease Without Bone Metastasis
Primary: Number of Participants With Progression Free Survival (PFS) — 9; 19; 6; 10 Participants
Phase 2 N=40 DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
Advanced Breast Cancer · HER2-positive Breast Cancer · Brain Metastases
Primary: 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) — 1; 7 Participants
Phase 2 N=56 A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
Locally Recurrent · Metastatic Breast Cancer ( HER2 Negative)
Primary: Objective Response Rate (ORR) — 28.6 Percentage of participants
Phase 2 N=99 Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Breast Cancer
Primary: Objective Response Rate (ORR) (Phase II) — 0; 5; 14 Participants